Classify every gene variant. Match every patient to the right drug.
Powered by geneSlice™, our world-leading proprietary platform, we generate variant-level functional data at scale — enabling drug developers across oncology and rare genetic diseases to stratify patients, de-risk clinical trials, and expand labels on evidence, not assumption.
Building the functional data precision medicine demands.
Most gene variants in cancer and rare disease are Variants of Uncertain Significance (VUS), leaving targeted therapies out of reach for patients who could benefit. And even well-established disease-causing variants need deep functional understanding to drive the patient stratification, biomarker integration, and label expansion that modern precision medicine demands.
Using geneSlice™, our proprietary gene editing platform, we build high-throughput functional assays that resolve gene variants, including pathogenic and VUS gene variants, into actionable classifications for targeted treatment — so drug developers can guide patient selection, de-risk clinical trials, expand label eligibility, and accelerate precision medicine projects.
From VUS to confirmed pathogenic, most patient variants have never been functionally tested for drug response.
For most clinically actionable genes, only a very small fraction of patient variants is functionally tested for drug responses. The vast majority of gene variants — pathogenic and VUS gene variants — remain functionally uncharacterised for treatment response, leaving trial design and treatment decisions without the variant-level data they need.
Variant by variant, at scale.
For each variant of interest, we engineer a cell model, measure how it responds to your drug or drug class, and read out a variant-level functional score. The workflow scales: data per variant, at the throughput modern drug development requires, scaling to thousands of variants per gene.
Every disease area, the same stakes.
In rare genetic disease, oncology, neurodegenerative, and cardiovascular conditions, mis-stratification costs the same — a patient enrolled who will not respond, or a patient excluded who would have.
Variant-level functional data resolves this. It confirms which variants are truly pathogenic, separates loss-of-function from partial-function, and predicts how a candidate therapy will perform across the full variant spectrum — before any patient is exposed.
Every disease area has its own complexity. Every variant has its own story. Every patient who carries one deserves an answer built on evidence, not assumption.
Every patient counts.
Two workflows, one platform
Every project begins with a consultation. From there, projects run on one of two flows — a productised variant-library workflow, or a bespoke design for more specialised needs.
Variant library workflow
Consultation
Scope the target, cell model, and functional assay.
Cell model development
geneSlice-powered cell model build.
Variant library & screening
Library construction, delivery, and functional assays.
Data delivery
Functional scores, variant-level classifications, resistance maps, annotated databases.
Bespoke workflow
Consultation
Scientific question and assay design.
Bespoke assay design
Custom cell-model build and tailored readouts.
Execution
Functional assays, arrayed screens, and bioinformatics.
Data delivery
Functional scores, variant-level classifications, and agreed deliverables.
Total timeline: typically 6–12 months for variant library projects; bespoke projects scoped per project. See Technology for the full process.
Functional genomics, end to end
Oncology
Variant classification for patient stratification, label expansion, and resistance anticipation.
Rare Genetic Diseases
Functional answers for rare disease, neurodegenerative, cardiovascular, and other genetically defined disorders.
Compound–Target Assay
Residue-level resistance and sensitivity maps for compound–target projects.
Custom Services
Bespoke assays for projects outside the standard shape.
CRISPR Therapeutics
Safety and QC support for CRISPR-based therapy developers.